Global Dyskinesia Pipeline Insight | Clinical Trials

New York, USA, Aug. 29, 2022 (GLOBE NEWSWIRE) — Global Dyskinesia Pipeline Insight | Clinical Trials Research Report 2022 by DelveInsight 

Dyskinesia Pipeline constitutes 40+ key companies continuously working towards developing 45+ Dyskinesia treatment therapies, analyzes DelveInsight

DelveInsight’s Dyskinesia Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Dyskinesia pipeline domain. 

Some of the essential takeaways from the Dyskinesia Pipeline report:

• DelveInsight’s Dyskinesia Pipeline analysis depicts a robust space with 40+ active players working to develop 45+ Dyskinesia pipeline treatment therapies. 
• Some of the key Dyskinesia companies proactively working to develop potential drug candidates to improve the Dyskinesia treatment options include names like Contera Pharma, VistaGen Therapeutics, Neurolixis, Celon Pharma, Addex Therapeutics, IRLAB Therapeutics AB, MAPLIGHT THERAPEUTICS, Melior Pharmaceuticals, Molomics, Teva Pharmaceutical, Luye Pharma Group, IMAC holdings, Neurocrine Biosciences, PolyCore Therapeutics, SOM Biotech, PharmaTher Inc., Appello Pharmaceutical, Sumitomo Pharma, Trevi Therapeutics, Sinopia Bioscience, SAGE Therapeutics, Adhera Therapeutics, and many more.
• Essential Dyskinesia pipeline therapies such as JM-010, CP-011, CPL 500036,NLX-112, Dipraglurant, IRL-790, ML-007, Mesocarb, Ketamine, Deutetrabenazine, LPM-3770164, PCT-3012, AQW051, DSP-9632P, AV-101,T 111, SB-0107, SOM3366, and many others.
• In June 2022, Addex Therapeutics Ltd announced that it had terminated the Phase IIb/III study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson’s disease (PD-LID) due to the slow recruitment of patients.
• In March 2022, Neurocrine Biosciences, Inc. announced that its…